Why Ventyx is Still Undervalued: The Metsera Precedent Points Above $100
Eli Lilly's $1.2 billion bid for Ventyx Biosciences represents a starting point that could ultimately lead to an acquisition price 10x higher. Ventyx is now in the same position, except its strategic value is broader, its clinical validation stronger, and the competitive stakes are considerably higher. The